BeiGene’s Biologics License Application for Tevimbra^® (Tislelizumab) for First-Line Gastric or Gastroesophageal Junction Cancers Accepted by FDA

BeiGene, Ltd. announced that the US FDA has accepted a Biologics License Application for TEVIMBRA® , in combination with fluoropyrimidine- and platinum-containing chemotherapy, for the treatment of patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma.